000279900 001__ 279900
000279900 005__ 20250824001659.0
000279900 0247_ $$2doi$$a10.1002/alz.70347
000279900 0247_ $$2pmid$$apmid:40660741
000279900 0247_ $$2ISSN$$a1552-5260
000279900 0247_ $$2ISSN$$a1552-5279
000279900 0247_ $$2altmetric$$aaltmetric:179480622
000279900 037__ $$aDZNE-2025-00860
000279900 041__ $$aEnglish
000279900 082__ $$a610
000279900 1001_ $$aMcCullough, Austin$$b0
000279900 245__ $$aRegional effects of gantenerumab on neuroimaging biomarkers in the DIAN-TU-001 trial.
000279900 260__ $$aHoboken, NJ$$bWiley$$c2025
000279900 3367_ $$2DRIVER$$aarticle
000279900 3367_ $$2DataCite$$aOutput Types/Journal article
000279900 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1755680933_25772
000279900 3367_ $$2BibTeX$$aARTICLE
000279900 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000279900 3367_ $$00$$2EndNote$$aJournal Article
000279900 520__ $$aMonoclonal anti-amyloid therapies are now accessible, but how these treatments influence changes within the brain is still not clear. We investigated overall and regional change in amyloid removal, glucose metabolism, and atrophy in trial participants with dominantly inherited Alzheimer's disease (DIAD).In the DIAN-TU-001 trial, 92 carriers received gantenerumab or placebo and underwent serial neuroimaging assessments including [11C]-Pittsburgh compound-B (PiB) positron emission tomography (PET), [18F]-fluoro-2-deoxyglucose (FDG) PET, and magnetic resonance imaging (MRI).Gantenerumab significantly reduced PiB-PET uptake overall and in most regions and showed no changes in FDG-PET or MRI measures. Drug effects were associated with baseline PiB-PET uptake, and the largest effects occurred in medial regions.Treated DIAD participants, and especially those with higher amyloid burden, showed a decrease in PiB-PET uptake, which was more pronounced in the basal ganglia and medial frontal structures. These results may inform patient response and future drug trial design.Gantenerumab unevenly decreased Aβ burden as measured by PiB-PET across brain regions. The strongest decrease in PiB-PET uptake was in basal ganglia and medial frontal structures. Variable drug effect on Aβ was partly due to the amount of burden present before treatment. There was no regional effect on FDG-PET metabolism or MRI volumetrics after 4 years.
000279900 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x0
000279900 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x1
000279900 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000279900 650_7 $$2Other$$aDIAN‐TU
000279900 650_7 $$2Other$$aFDG‐PET
000279900 650_7 $$2Other$$aMRI measures
000279900 650_7 $$2Other$$aPET
000279900 650_7 $$2Other$$aamyloid targeted monoclonal antibody
000279900 650_7 $$2Other$$aautosomal dominant Alzheimer's disease (ADAD)
000279900 650_7 $$2Other$$adominantly inherited Alzheimer's disease (DIAD)
000279900 650_7 $$2Other$$agantenerumab
000279900 650_7 $$2Other$$aimaging outcomes
000279900 650_7 $$2Other$$aregional PiB‐PET uptake
000279900 650_7 $$2Other$$aregional variability
000279900 650_7 $$2NLM Chemicals$$aAntibodies, Monoclonal, Humanized
000279900 650_7 $$04DF060P933$$2NLM Chemicals$$agantenerumab
000279900 650_7 $$2NLM Chemicals$$aBiomarkers
000279900 650_7 $$2NLM Chemicals$$aThiazoles
000279900 650_7 $$00Z5B2CJX4D$$2NLM Chemicals$$aFluorodeoxyglucose F18
000279900 650_7 $$2NLM Chemicals$$aAniline Compounds
000279900 650_7 $$2NLM Chemicals$$a2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole
000279900 650_7 $$2NLM Chemicals$$aAmyloid beta-Peptides
000279900 650_2 $$2MeSH$$aHumans
000279900 650_2 $$2MeSH$$aAlzheimer Disease: drug therapy
000279900 650_2 $$2MeSH$$aAlzheimer Disease: diagnostic imaging
000279900 650_2 $$2MeSH$$aAlzheimer Disease: genetics
000279900 650_2 $$2MeSH$$aAlzheimer Disease: pathology
000279900 650_2 $$2MeSH$$aPositron-Emission Tomography
000279900 650_2 $$2MeSH$$aMale
000279900 650_2 $$2MeSH$$aFemale
000279900 650_2 $$2MeSH$$aMagnetic Resonance Imaging
000279900 650_2 $$2MeSH$$aBrain: diagnostic imaging
000279900 650_2 $$2MeSH$$aBrain: drug effects
000279900 650_2 $$2MeSH$$aBrain: pathology
000279900 650_2 $$2MeSH$$aBrain: metabolism
000279900 650_2 $$2MeSH$$aAntibodies, Monoclonal, Humanized: therapeutic use
000279900 650_2 $$2MeSH$$aAntibodies, Monoclonal, Humanized: pharmacology
000279900 650_2 $$2MeSH$$aNeuroimaging
000279900 650_2 $$2MeSH$$aMiddle Aged
000279900 650_2 $$2MeSH$$aBiomarkers: metabolism
000279900 650_2 $$2MeSH$$aThiazoles
000279900 650_2 $$2MeSH$$aFluorodeoxyglucose F18
000279900 650_2 $$2MeSH$$aAniline Compounds
000279900 650_2 $$2MeSH$$aAged
000279900 650_2 $$2MeSH$$aAmyloid beta-Peptides: metabolism
000279900 693__ $$0EXP:(DE-2719)DIAN-20090101$$5EXP:(DE-2719)DIAN-20090101$$eLongitudinal Study on Dominantly Inherited Alzheimer's Disease$$x0
000279900 7001_ $$aChen, Charles D$$b1
000279900 7001_ $$aGordon, Brian A$$b2
000279900 7001_ $$aJoseph-Mathurin, Nelly$$b3
000279900 7001_ $$aJack, Clifford R$$b4
000279900 7001_ $$aKoeppe, Robert$$b5
000279900 7001_ $$aHornbeck, Russ$$b6
000279900 7001_ $$aKoudelis, Deborah$$b7
000279900 7001_ $$aMcKay, Nicole S$$b8
000279900 7001_ $$aHobbs, Diana A$$b9
000279900 7001_ $$aFlores, Shaney$$b10
000279900 7001_ $$aKeefe, Sarah J$$b11
000279900 7001_ $$aAggarwal, Neelum T$$b12
000279900 7001_ $$aAllegri, Ricardo F$$b13
000279900 7001_ $$aBerman, Sarah B$$b14
000279900 7001_ $$aBird, Thomas$$b15
000279900 7001_ $$aBlack, Sandra E$$b16
000279900 7001_ $$aBrooks, William S$$b17
000279900 7001_ $$aChhatwal, Jasmeer P$$b18
000279900 7001_ $$aDay, Gregory S$$b19
000279900 7001_ $$aFarlow, Martin R$$b20
000279900 7001_ $$aFox, Nick C$$b21
000279900 7001_ $$aGauthier, Serge$$b22
000279900 7001_ $$aHonig, Lawrence S$$b23
000279900 7001_ $$aHsiung, Ging-Yuek$$b24
000279900 7001_ $$0P:(DE-2719)2000010$$aJucker, Mathias$$b25$$udzne
000279900 7001_ $$0P:(DE-2719)2811659$$aLevin, Johannes$$b26$$udzne
000279900 7001_ $$aMasellis, Mario$$b27
000279900 7001_ $$aMasters, Colin$$b28
000279900 7001_ $$aMendez, Patricio Chrem$$b29
000279900 7001_ $$aRingman, John M$$b30
000279900 7001_ $$aSnider, B Joy$$b31
000279900 7001_ $$aSalloway, Stephen$$b32
000279900 7001_ $$aSchofield, Peter R$$b33
000279900 7001_ $$aShimada, Hiroyuki$$b34
000279900 7001_ $$aSuzuki, Kazushi$$b35
000279900 7001_ $$avan Dyck, Christopher H$$b36
000279900 7001_ $$aKlein, Gregory$$b37
000279900 7001_ $$aClifford, David B$$b38
000279900 7001_ $$aCruchaga, Carlos$$b39
000279900 7001_ $$aHassenstab, Jason$$b40
000279900 7001_ $$aLi, Yan$$b41
000279900 7001_ $$aMcDade, Eric$$b42
000279900 7001_ $$aMills, Susan$$b43
000279900 7001_ $$aMorris, John C$$b44
000279900 7001_ $$aPerrin, Richard J$$b45
000279900 7001_ $$aSupnet-Bell, Charlene$$b46
000279900 7001_ $$aWang, Guoqiao$$b47
000279900 7001_ $$aXiong, Chengjie$$b48
000279900 7001_ $$aBateman, Randall J$$b49
000279900 7001_ $$aBenzinger, Tammie L S$$b50
000279900 7001_ $$aTeam, DIAN-TU Study$$b51$$eCollaboration Author
000279900 773__ $$0PERI:(DE-600)2201940-6$$a10.1002/alz.70347$$gVol. 21, no. 7, p. e70347$$n7$$pe70347$$tAlzheimer's and dementia$$v21$$x1552-5260$$y2025
000279900 8564_ $$uhttps://pub.dzne.de/record/279900/files/DZNE-2025-00860%20SUP.zip
000279900 8564_ $$uhttps://pub.dzne.de/record/279900/files/DZNE-2025-00860.pdf$$yOpenAccess
000279900 8564_ $$uhttps://pub.dzne.de/record/279900/files/DZNE-2025-00860.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000279900 909CO $$ooai:pub.dzne.de:279900$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000279900 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000010$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b25$$kDZNE
000279900 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811659$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b26$$kDZNE
000279900 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x0
000279900 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x1
000279900 9141_ $$y2025
000279900 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-06
000279900 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-06
000279900 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bALZHEIMERS DEMENT : 2022$$d2025-01-06
000279900 915__ $$0LIC:(DE-HGF)CCBYNC4$$2HGFVOC$$aCreative Commons Attribution-NonCommercial CC BY-NC 4.0
000279900 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2025-01-06$$wger
000279900 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-06
000279900 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bALZHEIMERS DEMENT : 2022$$d2025-01-06
000279900 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-06
000279900 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000279900 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-06
000279900 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-01-06
000279900 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-06
000279900 9201_ $$0I:(DE-2719)1210001$$kAG Jucker$$lCell Biology of Neurological Diseases$$x0
000279900 9201_ $$0I:(DE-2719)1111016$$kAG Levin$$lClinical Neurodegeneration$$x1
000279900 9201_ $$0I:(DE-2719)1111015$$kClinical Research (Munich)$$lClinical Research (Munich)$$x2
000279900 980__ $$ajournal
000279900 980__ $$aVDB
000279900 980__ $$aUNRESTRICTED
000279900 980__ $$aI:(DE-2719)1210001
000279900 980__ $$aI:(DE-2719)1111016
000279900 980__ $$aI:(DE-2719)1111015
000279900 9801_ $$aFullTexts